Sources and References

Primary textbook — No required textbook; supplemental readings available through AccessPharmacy (McGraw-Hill) via the University library.

Supplementary texts — DiPiro JT, Yee GC, Posey LM, et al. Pharmacotherapy: A Pathophysiologic Approach, 12th ed. McGraw-Hill, 2023. Brunton LL, Knollmann BC, eds. Goodman & Gilman’s The Pharmacological Basis of Therapeutics, 14th ed. McGraw-Hill, 2023.

Online resources — Health Canada Drug Product Database (https://www.canada.ca/en/health-canada/services/drugs-health-products); Compendium of Pharmaceuticals and Specialties (CPS/RxTx, Canadian Pharmacists Association); FDA Drug Approvals and Databases (https://www.fda.gov/drugs); ClinicalTrials.gov; ICH Guidelines (https://www.ich.org); WHO Essential Medicines List (https://www.who.int/medicines); NAPRA National Drug Scheduling System (https://www.napra.ca).

Chapter 1: The Pharmacy Profession — History, Scope, and Identity

Introduction to Pharmacy as a Discipline

Pharmacy is among the oldest of the health professions, yet it is also one of the most dynamic, continuously reinventing itself in response to new scientific knowledge, evolving drug therapies, changing health systems, and expanding patient needs. At its core, pharmacy is the science and art of preparing, dispensing, and providing information about medicines — but this definition, while accurate, only hints at the full scope of what contemporary pharmacists do. Modern pharmacy practice encompasses medication therapy management, chronic disease monitoring, immunization, minor ailment prescribing (in provinces such as Ontario, Alberta, and New Brunswick), collaborative prescribing, and a growing range of patient-centred services that extend far beyond counting pills and labeling bottles.

The professional identity of a pharmacist is grounded in a deep body of pharmaceutical science — an understanding of how drugs are discovered, synthesized, formulated, absorbed, distributed, metabolized, and eliminated, and how they interact with biological targets to produce their effects. Without this mechanistic foundation, the clinical judgements that pharmacists make every day — detecting drug interactions, identifying contraindications, counselling patients on proper use — would be impossible. PHARM 150 exists to introduce that foundation and to situate it within the broader landscape of Canadian pharmacy practice, the healthcare system, and the pharmaceutical industry. The word “pharmacy” derives from the Greek pharmakon, meaning both remedy and poison — a duality that captures something essential about the nature of drugs. Every drug is, in principle, a poison at a high enough dose, and every poison may have therapeutic utility at the right dose and in the right context. This pharmacological duality, formalized later in the concept of the therapeutic index, has been understood intuitively since ancient times.

What has changed across millennia is the precision with which humans can identify therapeutic agents, understand their mechanisms, characterize their risks, and deliver them reliably to patients. The transformation of pharmacy from an apothecary’s craft into a rigorously scientific discipline has taken place over roughly two centuries, accelerating exponentially in the second half of the twentieth century with the development of molecular biology, combinatorial chemistry, genomics, and the technologies that enable high-throughput drug discovery. Today, the pharmacist practices at the intersection of this scientific tradition and the human dimension of patient care — a position that demands both deep expertise and genuine compassion.

Historical Roots of Pharmacy

The history of pharmacy is inseparable from the history of medicine. In ancient Mesopotamia, healers recorded drug recipes on clay tablets; the Ebers Papyrus from ancient Egypt, dating to approximately 1550 BCE, contains hundreds of medicinal formulas using plant, animal, and mineral ingredients. The ancient Greeks, particularly Dioscorides in his first-century text De Materia Medica, systematized knowledge of medicinal plants in a manner that remained authoritative for over a thousand years. Islamic scholars during the Golden Age of Islamic medicine — figures such as Ibn Sina (Avicenna), whose Canon of Medicine was widely used in European universities well into the seventeenth century — preserved and greatly extended classical pharmacological knowledge, introducing concepts of drug standardization and quality testing that were centuries ahead of their time. The medieval Islamic pharmacy, called the saydalani, was the direct precursor of the European apothecary.

In medieval and early modern Europe, the apothecary emerged as a distinct trade separate from the physician. Apothecaries compounded and dispensed remedies, and their shops — stocked with exotic spices, plant extracts, mineral salts, and animal products — were the precursors of the modern pharmacy. The establishment of the first pharmacopoeias, standardized references listing official drugs and their preparation, marked a critical step toward scientific pharmacy. The Pharmacopoeia Londinensis of 1618 and the later United States Pharmacopeia of 1820 provided authoritative standards that began to regulate what could be sold as medicine and how it should be prepared. In Canada, the British Pharmacopoeia was the authoritative reference until the establishment of the Canadian pharmacopoeia traditions aligned with international standards.

The nineteenth and twentieth centuries saw the transformation of pharmacy from a craft into a science. The isolation of morphine from opium by Friedrich Sertürner in 1804 — the first time a pure active compound had been extracted from a plant drug — heralded the era of alkaloid chemistry and demonstrated that the therapeutic power of plant preparations resided in specific chemical entities. This insight drove a revolution: quinine from cinchona bark, cocaine from coca leaves, digitalis glycosides from foxglove, salicylic acid from willow bark (which would eventually be acetylated to become aspirin). By the early twentieth century, synthetic organic chemistry had made it possible to design and manufacture novel compounds in the laboratory, and the pharmaceutical industry as we know it began to take shape.

The sulfonamide era of the 1930s demonstrated that synthetic organic chemistry could produce drugs effective against infectious diseases, transforming the treatment of bacterial infections before the discovery of penicillin. Alexander Fleming’s serendipitous observation of penicillin’s antibacterial activity in 1928, and the subsequent development of penicillin as a clinical agent by Florey and Chain during World War II, inaugurated the antibiotic era and saved millions of lives. The decades following World War II saw extraordinary pharmacological innovation: beta-blockers, calcium channel blockers, and ACE inhibitors revolutionizing cardiovascular medicine; antipsychotics and antidepressants beginning to address previously untreatable psychiatric conditions; corticosteroids transforming inflammatory and immune-mediated disease management; and the development of oral contraceptives with profound societal implications.

The Evolution of Canadian Pharmacy Education

Canadian pharmacy education has undergone a fundamental transformation since the early 2000s, shifting from a Bachelor of Science in Pharmacy (BSc Pharm) degree — which emphasized pharmaceutical sciences — to the Doctor of Pharmacy (PharmD) — which integrates those sciences with deep clinical training in patient assessment, drug therapy problem identification and resolution, and collaborative care. The University of Waterloo School of Pharmacy graduated its first PharmD class in 2012; most other Canadian pharmacy schools completed their transitions to the entry-to-practice PharmD around the same time. This educational evolution reflects and reinforces the expanded scope of pharmacy practice described above.

The curriculum of a Canadian entry-to-practice PharmD program is organized around the competency frameworks developed by the Association of Faculties of Pharmacy of Canada (AFPC) and aligned with the NAPRA Professional Competencies for Canadian Pharmacists at Entry to Practice. These frameworks define what a pharmacist must know and be able to do upon graduation, spanning pharmaceutical sciences (pharmacology, medicinal chemistry, pharmaceutical analysis, pharmacokinetics), clinical sciences (therapeutics, pharmacogenomics, drug information), professional practice skills (patient assessment, communication, documentation, clinical decision-making), and professional roles (ethical practice, leadership, interprofessional collaboration, population health). PHARM 150 introduces students to all of these domains at an introductory level, establishing a conceptual framework that will be elaborated across the remaining three years of the program.

Chapter 2: Foundational Pharmacology — Pharmacodynamics

Drug–Receptor Interactions

Pharmacodynamics is the study of how drugs affect the body — the relationship between drug concentration and pharmacological effect. The vast majority of drugs produce their effects by binding to specific macromolecular targets, most commonly proteins, and altering their activity. The concept of drug receptors was formulated in the late nineteenth and early twentieth centuries by Paul Ehrlich, who spoke of “magic bullets” — molecules that would selectively bind to pathogens or diseased cells without harming healthy tissue — and by John Newport Langley, who proposed on the basis of drug antagonism experiments that drugs act on specific “receptive substances” in tissues. The subsequent development of receptor theory by A.J. Clark, E.J. Ariens, and R.P. Stephenson provided the mathematical and conceptual framework that remains foundational today.

The four major classes of drug receptors reflect four broad mechanisms by which drugs alter cell function. Ligand-gated ion channels, such as the nicotinic acetylcholine receptor, the GABA-A receptor, and the ionotropic glutamate receptors, respond to ligand binding by opening or closing a transmembrane ion channel within milliseconds, producing rapid changes in membrane potential. These receptors are pentameric or tetrameric protein complexes; drug binding at orthosteric (agonist) or allosteric sites alters the probability of channel opening. Benzodiazepines, for example, act as positive allosteric modulators of the GABA-A receptor: they do not open the chloride channel themselves, but increase the frequency of channel opening in response to GABA, enhancing inhibitory neurotransmission and producing anxiolytic, sedative, anticonvulsant, and muscle-relaxant effects. This distinction between direct agonism and allosteric modulation is clinically important because benzodiazepines cannot cause the fatal respiratory depression associated with direct GABA-A agonists when administered alone at any dose; they require endogenous GABA to produce their effect.

G protein-coupled receptors (GPCRs) constitute the largest family of drug targets in the human genome, with over 800 members. GPCRs are integral membrane proteins that span the lipid bilayer seven times. When activated by agonist binding, they undergo conformational changes that allow coupling to heterotrimeric G proteins on the intracellular face of the membrane. The G protein dissociates, and its subunits regulate effector enzymes (adenylyl cyclase, phospholipase C) or ion channels, producing changes in second messenger concentrations — cyclic AMP, inositol trisphosphate, diacylglycerol, intracellular calcium — that propagate the signal into the cell. Drugs targeting GPCRs include beta-adrenergic receptor blockers (metoprolol, bisoprolol) used in heart failure and hypertension, opioid receptor agonists (morphine, fentanyl, oxycodone) used in pain management, muscarinic receptor antagonists (tiotropium, ipratropium) used in obstructive lung disease, and serotonin receptor agonists and antagonists used in migraine, nausea, and psychiatric disorders.

Receptor tyrosine kinases (RTKs) mediate the actions of growth factors, insulin, and many cytokines. Ligand binding to the extracellular domain promotes receptor dimerization and autophosphorylation of tyrosine residues on the intracellular domain, activating downstream signaling cascades including the MAP kinase pathway and the PI3K-Akt pathway. Many cancer driver mutations result in constitutive activation of RTKs; targeted cancer therapies such as imatinib (BCR-ABL inhibitor in CML), erlotinib and gefitinib (EGFR inhibitors in non-small cell lung cancer), and trastuzumab (anti-HER2 antibody in breast cancer) exploit this biology to achieve selective cancer cell killing with reduced toxicity to normal tissues compared to cytotoxic chemotherapy.

Nuclear receptors are transcription factors activated by lipophilic ligands that cross the plasma membrane and bind in the cytoplasm or nucleus. The glucocorticoid receptor, activated by cortisol and synthetic glucocorticoids such as prednisone and dexamethasone, mediates powerful anti-inflammatory and immunosuppressive effects by altering gene expression programs — upregulating anti-inflammatory genes and downregulating pro-inflammatory cytokine genes. The mineralocorticoid, androgen, estrogen, and thyroid hormone receptors similarly regulate programs of gene expression governing development, metabolism, and reproductive physiology. The effects of nuclear receptor-targeted drugs are characteristically slower in onset (hours to days) than those of ion channel or GPCR-targeted drugs, reflecting the time required for new protein synthesis in response to changes in gene expression.

Agonists, Antagonists, and the Dose-Response Relationship

The magnitude of a drug’s pharmacological effect depends on its concentration at the site of action and its intrinsic efficacy at the receptor. A full agonist, when it binds and activates the receptor, can elicit the maximum possible tissue response — 100% of E_max. A partial agonist, even when it occupies all available receptors, can achieve only a fraction of E_max because it stabilizes a receptor conformation with lower intrinsic activity than the fully active conformation. Partial agonists have the interesting clinical property that they act as agonists in conditions of low endogenous agonist activity, and as effective antagonists in conditions of high endogenous agonist activity (competing with the full endogenous agonist for receptor occupancy). Buprenorphine, a partial agonist at the mu-opioid receptor, exploits this property: in opioid use disorder, it provides sufficient opioid receptor activation to prevent withdrawal symptoms and cravings, while its ceiling effect on respiratory depression makes overdose-related death less likely than with full mu-opioid agonists like heroin or fentanyl.

Competitive antagonists compete with agonists for the same binding site. Because this competition is reversible, increasing the agonist concentration can displace the antagonist and restore the maximum response; competitive antagonists shift the agonist concentration-response curve to the right without reducing E_max. Beta-blockers competitively antagonize the effects of catecholamines at beta-adrenergic receptors; in high-stress states where catecholamine concentrations are very high, the beta-blockade can be partially overcome, which is why beta-blocker dose titration must sometimes be escalated. Non-competitive antagonists bind to an allosteric site and reduce E_max regardless of agonist concentration. Irreversible antagonists (such as phenoxybenzamine, which alkylates alpha-adrenergic receptors) covalently modify the receptor, producing effects that persist until new receptor protein is synthesized — a duration of action measured in days rather than hours.

The therapeutic index is a critical safety concept relating efficacy to toxicity:

Drugs with a high therapeutic index — most penicillin antibiotics, for example, where doses hundreds of times higher than those needed for antibacterial effect can be administered without toxicity — are forgiving in clinical use. Drugs with a low therapeutic index — warfarin, digoxin, lithium, phenytoin, aminoglycoside antibiotics, methotrexate — require careful dose individualization, therapeutic drug monitoring, and close attention to factors that alter pharmacokinetics (renal function, drug interactions, age) because the margin between therapeutic and toxic concentrations is narrow. In Canadian pharmacy practice, therapeutic drug monitoring programs for narrow therapeutic index drugs are integral to both hospital pharmacy and community care.

Receptor Regulation and Drug Tolerance

Receptor systems are not static; they adapt dynamically to prolonged drug exposure in ways that have important clinical consequences. The most clinically significant adaptive phenomena are tolerance — the diminishing response to a repeated dose of drug, requiring higher doses to achieve the same effect — and receptor up- or down-regulation, in which the number or sensitivity of receptors changes in response to chronic agonist or antagonist exposure.

Tolerance to opioid analgesics is a well-recognized phenomenon that develops with chronic use and has multiple contributing mechanisms. Cellular tolerance involves desensitization of individual mu-opioid receptors through phosphorylation by G protein-coupled receptor kinases (GRKs) and subsequent uncoupling of the receptor from its G protein, reducing signal transduction efficiency. Internalization of the receptor following prolonged agonist exposure reduces the number of surface receptors available for drug binding. Neuroadaptive changes at the level of pain-modulating circuits — including upregulation of adenylyl cyclase activity (compensatory to the initial cAMP suppression by opioid receptors) — contribute to the development of dependence, such that abrupt cessation of opioid exposure produces a withdrawal syndrome characterized by the opposite of the acute opioid effects: anxiety, agitation, diarrhea, tachycardia, diaphoresis, and severe pain. Understanding these mechanisms helps pharmacists counsel patients on opioid use, recognize signs of opioid use disorder, and support appropriate tapering regimens when opioid discontinuation is necessary.

Chapter 3: Foundational Pharmacology — Pharmacokinetics

Absorption and Bioavailability

Pharmacokinetics describes what the body does to a drug — the processes of absorption, distribution, metabolism, and excretion (ADME) that determine how drug concentrations change over time. These processes collectively determine the time course and magnitude of drug exposure at the site of action, and understanding them is essential for selecting appropriate doses, dosing intervals, and routes of administration, and for predicting how pharmacokinetic parameters will change in patients with organ impairment or interacting drugs.

Absorption is the process by which a drug moves from its site of administration into the systemic circulation. For orally administered drugs — the most common and preferred route — absorption occurs primarily in the small intestine. The small intestine is ideally suited for drug absorption: its enormous surface area (approximately 200 m², created by the circular folds of Kerckring, the villi, and the microvilli of the brush border), rich blood supply (ensuring rapid removal of absorbed drug and maintenance of a favorable concentration gradient), and slightly alkaline luminal pH create conditions that favour absorption of most drug molecules. The fraction of an administered dose that reaches the systemic circulation unchanged is called bioavailability (F). Intravenous administration achieves 100% bioavailability by definition; oral bioavailability is reduced by incomplete absorption across the gut wall and by first-pass metabolism in the intestinal wall and liver.

The Biopharmaceutics Classification System (BCS) categorizes drugs into four classes based on their aqueous solubility and membrane permeability, providing a framework for predicting absorption behavior and guiding formulation development. Class I drugs (high solubility, high permeability) such as metoprolol and verapamil are generally well absorbed; their absorption rate is primarily limited by gastric emptying. Class II drugs (low solubility, high permeability) such as ibuprofen and griseofulvin have dissolution-limited absorption that can be improved by particle size reduction, amorphous formulations, or solid dispersions in hydrophilic polymers. Class III drugs (high solubility, low permeability) such as cimetidine and acyclovir have membrane-permeability-limited absorption that may be improved by intestinal permeability enhancers or prodrug strategies. Class IV drugs (low solubility, low permeability) such as hydrochlorothiazide and furosemide at high doses present the greatest formulation challenges.

Distribution and Protein Binding

Distribution is the reversible transfer of drug from the systemic circulation into tissues. The apparent volume of distribution (V_d) is a conceptual parameter relating the total amount of drug in the body to the plasma drug concentration:

A large V_d indicates extensive tissue distribution — the drug preferentially partitions into peripheral tissues, leaving relatively little in plasma. Chloroquine has a V_d of approximately 200-800 L/kg, extraordinarily large because it avidly accumulates in tissues, particularly in lysosomes. Lipophilic drugs — those with high octanol-water partition coefficients — tend to have large V_d values because they partition into adipose tissue and other lipid-rich compartments; such drugs also have slow elimination because only the fraction in plasma is available for hepatic metabolism and renal excretion.

Drug binding to plasma proteins — primarily albumin (for acidic drugs) and alpha-1-acid glycoprotein (for basic drugs) — is an important determinant of distribution and elimination. The protein-bound fraction is pharmacologically inactive and unavailable for metabolism and excretion; only the free (unbound) fraction is pharmacologically active and can cross cell membranes to reach intracellular targets. Warfarin is approximately 99% bound to albumin; the 1% free fraction determines pharmacological activity. Displacement interactions — in which a competing drug displaces warfarin from albumin binding sites — can theoretically increase the free fraction and potentiate anticoagulant effect, though in practice the clinical significance of pure displacement interactions is often modest because the displaced drug is also more rapidly metabolized and excreted. The key clinical implications of protein binding are in interpreting serum drug concentrations in hypoalbuminaemic patients (as seen in cirrhosis, nephrotic syndrome, or malnutrition), where a “normal” total drug concentration may mask a dangerously elevated free drug concentration.

Hepatic Drug Metabolism

Drug metabolism — the enzymatic transformation of drugs into metabolites — occurs primarily in the liver, which is anatomically and biochemically specialized for this function. The liver receives a dual blood supply (portal vein carrying absorbed drugs directly from the gut, and hepatic artery) and contains high concentrations of drug-metabolizing enzymes in the smooth endoplasmic reticulum of hepatocytes. The cytochrome P450 (CYP) superfamily is responsible for the oxidative metabolism of the majority of drugs, and understanding CYP enzymology — which enzymes metabolize which drugs, which drugs inhibit or induce which enzymes, and the clinical consequences of drug interactions mediated through CYP modulation — is one of the most practically important areas of pharmacokinetics for clinical pharmacy practice.

CYP3A4 is the most abundant hepatic CYP enzyme and metabolizes roughly 50% of drugs; CYP2D6 metabolizes approximately 25% of drugs despite being expressed at lower levels; CYP2C9, CYP2C19, CYP1A2, and CYP2E1 account for most of the remainder. CYP enzymes can be inhibited by many drugs, resulting in reduced clearance and elevated plasma concentrations of co-administered substrates — a potential source of toxicity. Fluconazole, an antifungal agent, is a potent inhibitor of CYP2C9 and a moderate inhibitor of CYP3A4; co-administration of fluconazole with warfarin (a CYP2C9 substrate) can dramatically reduce warfarin clearance and cause dangerous over-anticoagulation. CYP enzymes can also be induced — their expression upregulated — by drugs such as rifampin, carbamazepine, phenytoin, and St. John’s Wort, which activate nuclear receptors (primarily PXR and CAR) that transcriptionally upregulate CYP genes. Rifampin induction of CYP3A4 can reduce the plasma concentrations of many co-administered drugs by 50-90%, potentially resulting in therapeutic failure.

Phase II metabolism involves conjugation reactions — glucuronidation (by UGT enzymes), sulfation (by SULT enzymes), acetylation (by NAT enzymes), methylation (by COMT, TPMT, HNMT), and glutathione conjugation — that add large, polar groups to drug molecules, dramatically increasing hydrophilicity and facilitating renal or biliary excretion. Glucuronidation is the most common Phase II reaction and is carried out by a family of UGT enzymes in the liver and intestinal wall. Morphine undergoes glucuronidation to morphine-3-glucuronide (inactive) and morphine-6-glucuronide (pharmacologically active, with significant opioid receptor affinity); in patients with renal impairment, morphine-6-glucuronide accumulates because it is renally cleared, potentially causing opioid toxicity even when morphine itself is dosed conservatively. This pharmacokinetic consideration — the accumulation of active metabolites in organ impairment — is a recurring theme in clinical pharmacy practice.

Renal Excretion and Clearance

The kidney is the primary route of excretion for most drugs and their metabolites. Renal drug excretion involves three processes: glomerular filtration (the passive passage of unbound drug from the glomerular capillaries into the Bowman’s capsule, driven by the hydrostatic pressure gradient), tubular secretion (active transport of drug from peritubular capillaries into the tubular lumen, mediated by organic anion transporters [OATs] and organic cation transporters [OCTs] in the proximal tubule), and tubular reabsorption (passive reabsorption of lipophilic, unionized drug from the tubular lumen back into the bloodstream). The interplay of these three processes determines the net renal clearance of a drug.

Renal clearance is critically dependent on glomerular filtration rate (GFR), and therefore on the health of the kidneys. In patients with chronic kidney disease (CKD), GFR is reduced, and drugs that are primarily renally excreted accumulate to higher-than-expected plasma concentrations unless doses are reduced. Dose adjustment in renal impairment is one of the most common and important pharmacokinetic interventions in clinical pharmacy, and the Cockcroft-Gault equation — which estimates creatinine clearance (used as a surrogate for GFR) from serum creatinine, age, weight, and sex — is the most widely used tool for this purpose:

This estimate has limitations in patients with unusual muscle mass (e.g., amputees, bodybuilders), acute kidney injury, and at extremes of age and weight, and the pharmacist must exercise clinical judgment in applying it.

Chapter 4: Drug Discovery — From Target to Clinical Candidate

Target Identification and Validation

The first and arguably most critical step in drug discovery is identifying a molecular target — a biological entity whose modulation will produce a clinically beneficial effect — and validating that it genuinely plays the role attributed to it in disease pathophysiology. Target identification draws on diverse experimental approaches: genetic studies in model organisms to identify genes essential for disease-relevant processes; human genetic studies (genome-wide association studies, Mendelian randomization, rare variant analysis) to link specific gene variants to disease risk or protection; proteomics and metabolomics to characterize the molecular landscape of disease; and systems biology approaches that model the network of interactions governing complex phenotypes.

Validation is the process of building confidence that the identified target is genuinely causal in disease and that its modulation will produce the expected therapeutic benefit without unacceptable consequences. Genetic validation involves demonstrating that manipulation of the target gene (knockout, knockdown, mutation) produces a disease-relevant or protective phenotype in model organisms. Chemical validation involves demonstrating that a tool compound with well-characterized activity at the target produces therapeutic effects in a validated disease model. The highest level of validation — clinical validation — occurs when a drug targeting the protein produces clinical benefit in human trials. Drug discovery programs targeting chemically validated but not clinically validated targets carry substantially higher risk of failure in Phase II and III clinical trials; recognizing this distinction helps explain why most drug development programs fail and why clinical validation, while expensive and slow, provides irreplaceable evidence of target relevance in human disease.

High-Throughput Screening and Medicinal Chemistry

Once a validated target is available, the drug discovery campaign moves to identification of chemical matter that interacts with the target and modulates its activity. For small molecule drugs, the standard approach begins with high-throughput screening (HTS) of large compound libraries — pharmaceutical companies maintain collections ranging from hundreds of thousands to several million compounds screened in miniaturized 384-well or 1536-well plate formats using robotic liquid handling systems. Hits — compounds that show activity above a defined threshold in the primary assay — advance to confirmation testing, counter-screens to eliminate false positives (compounds that interfere with the assay readout rather than genuinely inhibiting the target), and selectivity profiling against related targets.

Medicinal chemistry is the iterative, hypothesis-driven process of modifying the chemical structure of hit compounds to simultaneously improve multiple properties: potency (measured as K_i or IC₅₀), selectivity (ensuring the compound acts at the desired target but not at other targets that could cause adverse effects), cell-based activity (confirming that potency in isolated biochemical assays translates to activity in living cells), metabolic stability (ensuring the compound survives long enough in the body to reach its target), solubility (ensuring it can be adequately dissolved and absorbed), and permeability (ensuring it can cross relevant biological barriers). The Lipinski “Rule of Five” — derived from an analysis of oral drugs approved by the FDA and proposing that good oral bioavailability is associated with molecular weight below 500 Da, cLogP below 5, fewer than 5 hydrogen bond donors, and fewer than 10 hydrogen bond acceptors — provides a useful heuristic for the physicochemical property space associated with oral drug candidates, though it is not a rigid rule and many excellent drugs violate one or more of these criteria.

From Lead Compound to Investigational New Drug

A lead compound that has been optimized in terms of in vitro potency, selectivity, metabolic stability, and drug-like physicochemical properties must still demonstrate efficacy and tolerability in animal models before it can be advanced to human testing. The preclinical in vivo program serves two purposes: proof-of-concept (demonstrating that the compound produces the expected pharmacological effect at tolerable exposures in an animal model of the target disease) and toxicology (characterizing the adverse effects produced at doses above the anticipated therapeutic range, establishing the no-observed-adverse-effect level [NOAEL], and identifying target organs of toxicity that will need to be monitored in human trials).

In Canada, before a new drug can be administered to human subjects, the sponsor must file a Clinical Trial Application (CTA) with Health Canada’s Therapeutic Products Directorate. The CTA package includes the investigational brochure (a comprehensive summary of the drug’s chemistry, pharmacology, pharmacokinetics, and preclinical safety data), the clinical protocol (the detailed study design and procedures), and evidence that the manufacturing process meets Good Manufacturing Practice (GMP) standards. Health Canada has 30 days to review the CTA and issue a notice of non-objection (allowing the trial to proceed) or a clinical hold (requiring additional information or modification of the protocol). The preclinical package submitted in the CTA must include adequate in vitro and in vivo pharmacology and pharmacokinetic data, and at minimum an assessment of acute and repeat-dose toxicity of sufficient duration to support the proposed human study duration.

Chapter 5: Clinical Drug Development — Phases I Through III and Beyond

Phase I: First-in-Human Studies

Phase I clinical trials are the first administration of an investigational drug to human subjects. They are typically conducted in twenty to eighty healthy volunteers (or in patients for drugs where exposure of healthy volunteers would be unethical, such as most oncology drugs and drugs for severe infectious diseases). The primary objectives of Phase I are to characterize the drug’s pharmacokinetics — how the body handles it at different doses and with multiple doses — and to establish the maximum tolerated dose (MTD) and the dose-limiting toxicities (DLTs).

A typical oncology Phase I trial uses a 3+3 dose escalation design: cohorts of three patients are treated at ascending doses; if no DLTs occur, the dose is escalated; if one of three patients experiences a DLT, three more patients are added at the same dose; if two or more of six patients experience DLTs, the dose escalation stops and the MTD is declared as the previous dose level. More recent Phase I designs use model-based approaches (the continual reassessment method [CRM]) that more efficiently identify the recommended Phase II dose by incorporating all available data into a Bayesian model that guides dose assignments in a principled way. Biomarkers of pharmacological activity — proof-of-mechanism biomarkers — are increasingly incorporated into Phase I designs to provide early evidence that the drug is engaging its target in patients, supporting the decision to proceed to Phase II.

For non-oncology drugs, Phase I trials in healthy volunteers typically include single-ascending-dose (SAD) studies that establish the pharmacokinetic profile and safety at individual doses, and multiple-ascending-dose (MAD) studies that characterize pharmacokinetics and safety with repeated dosing and assess for accumulation. Additional Phase I studies may include drug-drug interaction studies (examining how the investigational drug affects the pharmacokinetics of probe substrates of major CYP enzymes, and vice versa), food effect studies (comparing pharmacokinetics in the fed and fasted states), renal and hepatic impairment studies (characterizing how organ impairment affects drug exposure), and thorough QT studies (assessing the drug’s effect on cardiac repolarization, as delayed repolarization — reflected in a prolonged QTc interval on the electrocardiogram — can predispose to potentially fatal arrhythmias).

Phase II: Proof of Concept and Dose Finding

Phase II trials are conducted in a few hundred patients with the target disease and serve two main purposes: establishing proof of concept (demonstrating that the drug produces a measurable effect on a biologically relevant endpoint in patients) and identifying the dose or doses to carry forward into definitive Phase III trials. Phase II trials are often exploratory in nature — they may use adaptive designs that allow modifications to doses, sample sizes, or even study endpoints based on accumulating data — and they provide the first substantial safety database in the target patient population, which may have very different pharmacokinetics and tolerability from the healthy volunteers studied in Phase I.

The selection of the clinical endpoint for Phase II is a critical decision. A pharmacodynamic biomarker endpoint — measuring the drug’s effect on a biological process known to be causally related to the disease — can provide early evidence of activity with a smaller sample size than a clinical outcome endpoint (such as reduction in cardiovascular events or cancer recurrence). However, a positive biomarker endpoint does not guarantee a positive clinical outcome: many drugs that looked promising based on biomarker effects have failed in Phase III because the biomarker was not sufficiently predictive of clinical benefit, or because the drug’s adverse effects negated its benefits. The history of drug development is full of examples: drugs that lowered LDL cholesterol, raised HDL cholesterol, reduced blood glucose, or improved imaging endpoints that nonetheless failed to improve patient-centred outcomes in Phase III.

Phase III: Pivotal Trials for Regulatory Approval

Phase III trials are large, typically randomized and double-blinded, pivotal studies that provide definitive evidence of efficacy and characterize the safety profile in a patient population large enough to detect adverse events occurring at clinically meaningful frequencies. These are the studies that form the core of the regulatory submission — the New Drug Submission (NDS) in Canada, the New Drug Application (NDA) or Biologics License Application (BLA) in the United States — and their design, conduct, analysis, and reporting are subject to rigorous regulatory scrutiny.

The statistical analysis of Phase III trials is pre-specified in a statistical analysis plan (SAP) that must be finalized before data unblinding to prevent post-hoc manipulation of the analysis to achieve a statistically significant result. The primary endpoint — the single most clinically important outcome on which the trial’s success is judged — is designated in advance, and the statistical threshold for declaring success is set (typically a two-sided alpha of 0.05) in the SAP. Secondary endpoints provide supplementary information about the drug’s effects on other relevant outcomes, but their interpretation must be viewed with caution because multiple comparisons increase the risk of false-positive findings; pre-specified hierarchical testing procedures are used to control the overall type I error rate.

Post-Marketing Surveillance and Pharmacovigilance

Drug approval based on Phase III trial data does not mark the end of the evidence-generation process. Phase III trials, even large ones with thousands of participants, are too small to detect adverse drug reactions occurring at frequencies below approximately 1 in 1000 or 1 in 10,000. They also enroll carefully selected patient populations — excluding pregnant women, children, the elderly, and patients with severe renal or hepatic impairment — who may respond differently from the heterogeneous real-world patient population that will use the drug after approval. Post-marketing surveillance, collectively referred to as pharmacovigilance, is the systematic collection, monitoring, assessment, and interpretation of adverse drug reaction reports from the post-marketing period.

In Canada, the MedEffect Canada program (operated by Health Canada) is the national pharmacovigilance system to which healthcare providers, patients, and manufacturers can report suspected adverse drug reactions. Healthcare providers — including pharmacists — are encouraged but not mandated to report serious or unexpected adverse drug reactions; manufacturers are legally required to report adverse events that come to their attention within specified timeframes. The Canada Vigilance Program database contains over 600,000 adverse drug reaction reports and is used by Health Canada to detect safety signals — statistical or clinical patterns suggesting a possible causal association between a drug and an adverse event — that may warrant additional investigation or regulatory action such as label updates, risk mitigation strategies, or in rare cases market withdrawal.

Chapter 6: Drug Regulation in Canada — The Health Canada Framework

The New Drug Submission Process

When a pharmaceutical company has completed the clinical development program for a new drug and wishes to market it in Canada, it must file a New Drug Submission (NDS) with Health Canada’s Therapeutic Products Directorate (TPD). The NDS is an extraordinarily comprehensive document — typically comprising hundreds of thousands to millions of pages of data — organized according to the International Common Technical Document (CTD) format, which is a harmonized submission format accepted by regulatory agencies in Canada, the United States, Europe, Japan, and other ICH regions.

The CTD is organized into five modules. Module 1 contains administrative information and regional-specific documents (prescribing information draft, the product monograph in Canada). Module 2 contains summaries of the technical information in Modules 3, 4, and 5, and the overall clinical summary and benefit-risk assessment. Module 3 contains the complete pharmaceutical quality data — drug substance (API) chemistry, manufacturing, and controls; drug product (dosage form) composition, manufacturing process, and quality specifications; and stability data demonstrating that the product maintains its potency and safety over the proposed shelf life under the labelled storage conditions. Module 4 contains the complete nonclinical (preclinical) study reports. Module 5 contains the complete clinical study reports.

Health Canada’s review of an NDS involves multidisciplinary teams of scientists and physicians who evaluate the quality (pharmaceutical chemistry and manufacturing), safety (toxicology), and clinical (pharmacology/pharmacokinetics and clinical efficacy and safety) components of the submission in parallel. The standard review target timeline is 300 days for standard submissions and 180 days for Priority Review, which is available for drugs addressing serious life-threatening conditions with inadequate alternative therapies. Upon completing its review, Health Canada issues a Notice of Compliance (NOC) if the benefit-risk assessment is favourable, authorizing the drug for sale in Canada with the approved labeling contained in the Product Monograph.

Drug Scheduling in Canada

The National Association of Pharmacy Regulatory Authorities (NAPRA) administers the National Drug Scheduling System (NDSS), which assigns drugs to one of four schedules based on the level of professional oversight required for their safe sale and use. Understanding drug scheduling is fundamental to pharmacy practice because it defines the conditions under which different drugs can be sold and the professional obligations that attach to their sale.

The scheduling decision for a drug is based on several criteria: the potential for harm if misused or used without appropriate supervision; the need for professional assessment before use; the potential for drug interactions with other medications; the requirement for monitoring during use; the risk of abuse or dependence; and the extent of patient self-diagnosis and self-treatment risk. A drug can be rescheduled over its commercial lifetime as experience with the drug accumulates and as the evidence base for its safety in self-care settings grows. Many drugs have been moved from Schedule I (prescription only) to Schedule II (pharmacist-supervised sale) or Schedule III (self-selection) as post-marketing evidence established their safety profile. Oral emergency contraception (Plan B, containing levonorgestrel) is an example of a drug that was rescheduled in most Canadian provinces from Schedule I to Schedule II or III, improving access for patients who need time-sensitive treatment.

Chapter 7: Pharmacogenomics — Precision Pharmacy

Genetic Variation and Drug Metabolism

One of the most exciting frontiers in contemporary pharmacology and pharmacy practice is the recognition that genetic variation among individuals is a major — and often underappreciated — determinant of variability in drug response. People differ from one another in how efficiently they metabolize drugs, how sensitively they respond to pharmacological effects, and whether they are predisposed to specific adverse drug reactions. Much of this variability is heritable, rooted in polymorphisms in genes encoding drug-metabolizing enzymes, drug transporters, drug targets, and other proteins involved in drug disposition and action.

CYP2D6, which metabolizes approximately 25% of commonly used drugs including codeine, opioids, tricyclic antidepressants, selective serotonin reuptake inhibitors (some SSRIs), beta-blockers, antipsychotics, and tamoxifen, is perhaps the most clinically consequential example of pharmacogenomic variability. CYP2D6 is encoded by a highly polymorphic gene on chromosome 22q13.2, with more than 100 allelic variants identified. Individuals can be classified into four phenotypic categories: poor metabolizers (PMs, who carry two non-functional alleles), intermediate metabolizers (IMs, with one non-functional and one reduced-function allele), extensive metabolizers (EMs, the “normal” phenotype), and ultrarapid metabolizers (UMs, who carry gene duplications resulting in very high CYP2D6 activity). The frequency of these phenotypes varies substantially by ancestry: approximately 5-10% of European-ancestry individuals are CYP2D6 poor metabolizers, versus 1-2% of individuals of African or Asian ancestry; ultrarapid metabolism is substantially more common in individuals of North African and Middle Eastern ancestry.

Tamoxifen, used for five to ten years in estrogen receptor-positive breast cancer, is a prodrug that requires CYP2D6-mediated conversion to its active metabolite endoxifen, which is 30-100 times more potent than tamoxifen itself at the estrogen receptor. CYP2D6 poor metabolizers and patients taking strong CYP2D6 inhibitors (such as paroxetine or fluoxetine) have dramatically reduced endoxifen concentrations and may derive substantially less benefit from tamoxifen. This interaction has major clinical significance: SSRIs are commonly prescribed to breast cancer patients to manage tamoxifen-induced hot flashes, but paroxetine and fluoxetine — the most potent CYP2D6 inhibitors among the SSRIs — should generally be avoided in favour of CYP2D6-sparing alternatives such as venlafaxine or citalopram. This is a practical, actionable pharmacogenomic consideration that pharmacists can address at every tamoxifen prescription review.

HLA Pharmacogenomics and Immune-Mediated Reactions

Some of the most consequential pharmacogenomic associations link specific HLA alleles — genes encoding human leukocyte antigens, the proteins that present peptide fragments to T lymphocytes — to severe, immune-mediated adverse drug reactions. These reactions, though rare in the general population, can be life-threatening, and prospective genotyping before drug exposure represents one of the clearest implemented successes of pharmacogenomics in preventing drug harm.

The HLA-B57:01 allele is strongly associated with abacavir hypersensitivity reaction (ABC-HSR), occurring in approximately 5-8% of abacavir-treated patients who carry the allele. ABC-HSR is characterized by fever, rash, malaise, gastrointestinal symptoms, and respiratory symptoms that worsen with each dose and require drug discontinuation; re-challenge after discontinuation can cause an immediate, severe, and potentially fatal reaction. Prospective HLA-B57:01 screening before abacavir initiation — now standard of care internationally and recommended by Health Canada — virtually eliminates ABC-HSR. The HLA-B15:02 allele, carried primarily by individuals of Han Chinese, Thai, and other Southeast Asian ancestry, is strongly associated with Stevens-Johnson syndrome and toxic epidermal necrolysis induced by carbamazepine — severe, potentially fatal skin reactions that carry a mortality rate of 10-30%. Health Canada and international regulatory agencies require HLA-B15:02 testing before carbamazepine initiation in genetically at-risk patients. The HLA-A*31:01 allele, found more commonly in North Europeans, Japanese, and some other populations, is associated with maculopapular exanthema and drug reaction with eosinophilia and systemic symptoms (DRESS) due to carbamazepine. These HLA associations represent pharmacogenomics implemented at scale, demonstrating that genetic testing can prevent serious drug harm when the association is strong, the reaction is severe, the test is reliable, and an alternative drug is available.

Chapter 8: Biopharmaceuticals and Advanced Drug Therapies

Monoclonal Antibodies and the Age of Targeted Biotherapeutics

Biopharmaceuticals — drug substances derived from biological sources or produced by biological processes — have transformed the treatment of cancer, autoimmune diseases, infectious diseases, and metabolic disorders over the past four decades. The isolation of insulin from animal pancreatic tissue and its use in the treatment of type 1 diabetes beginning in the 1920s was the first example of a biopharmaceutical, but the field was truly revolutionized by the development of recombinant DNA technology in the 1970s and 1980s, which made it possible to express human proteins of therapeutic interest in microbial or mammalian cell factories at commercial scale.

Monoclonal antibodies (mAbs) are proteins produced by a single clone of B lymphocytes — or, in the therapeutic context, by hybridoma cells or engineered cell lines — and are therefore identical in their antigen-binding specificity. The therapeutic power of monoclonal antibodies lies in their exquisite target specificity, their long half-life (typically 2-3 weeks, due to neonatal Fc receptor recycling), and their versatility as scaffolds for diverse therapeutic mechanisms. Naked antibodies can neutralize target proteins (bevacizumab neutralizing VEGF in colorectal cancer), block receptor-ligand interactions (pertuzumab blocking HER2 dimerization), trigger Fc-mediated immune effector functions (rituximab engaging NK cells and complement to kill CD20-expressing B cells), or deplete target cells by antibody-dependent cellular cytotoxicity (ADCC) or complement-dependent cytotoxicity (CDC). Antibody-drug conjugates (ADCs) couple cytotoxic payloads to antibodies through chemical linkers, delivering potent cytotoxins selectively to antigen-expressing cancer cells while sparing normal tissues. Bispecific antibodies engage two different antigens simultaneously, enabling applications such as redirecting cytotoxic T cells to kill cancer cells regardless of T cell receptor specificity.

mRNA Vaccines and the New Vaccine Paradigm

The mRNA vaccines against SARS-CoV-2 developed by Pfizer-BioNTech and Moderna and authorized in Canada beginning in December 2020 represent both the most successful deployment of mRNA vaccine technology in history and a transformative proof of concept for a platform that had been under development for decades. mRNA vaccines work by delivering messenger RNA encoding a pathogen antigen — in this case, the prefusion-stabilized spike protein of SARS-CoV-2 — encapsulated in lipid nanoparticles (LNPs) into host cells after injection. The recipient’s own ribosomes translate the mRNA and produce the encoded spike protein; this antigen is then recognized by the immune system and stimulates the development of antibody responses and antigen-specific T cell immunity.

The mRNA used in these vaccines is modified in several ways to improve its performance. Pseudouridine substitutes for uridine in the mRNA sequence, reducing the innate immune recognition of the mRNA as foreign and increasing its translational efficiency. The 5’ cap structure and 3’ poly-A tail optimize mRNA stability and translation. The mRNA sequence is codon-optimized for efficient expression in human cells. Two proline substitutions in the spike protein coding sequence stabilize the protein in its prefusion conformation, which is more immunogenic than the post-fusion conformation. The lipid nanoparticle carrier — a four-component lipid mixture including an ionizable cationic lipid, a helper lipid, cholesterol, and a PEGylated lipid — protects the mRNA from degradation, facilitates cellular uptake by endocytosis, and promotes endosomal escape of the mRNA into the cytoplasm where it can be translated. The design of LNPs capable of efficiently delivering nucleic acids is a scientific achievement that took decades of research and enabled not only mRNA vaccines but also the siRNA therapeutic inclisiran (Leqvio), approved for LDL-C reduction, and the CRISPR-based gene therapy for sickle cell disease.

Chapter 9: The Canadian Healthcare System and Pharmacy’s Place Within It

Structure and Funding

The Canadian healthcare system is a publicly funded, provincially administered system organized around the principles of the Canada Health Act (1984): public administration, comprehensiveness, universality, portability, and accessibility. Each province and territory operates its own public health insurance plan that covers medically necessary physician services and hospital care; the federal government transfers funds to provinces through the Canada Health Transfer and sets national standards, but provinces have constitutional jurisdiction over health service delivery.

Prescription drugs are notably absent from the universal coverage guarantee of the Canada Health Act. Provincial and territorial drug benefit programs provide coverage for specific populations — seniors, social assistance recipients, high-cost drug users — and for drugs listed on provincial formularies. The Ontario Drug Benefit (ODB) program covers eligible residents including those over 65, residents of long-term care, and those receiving provincial social assistance. The federal Non-Insured Health Benefits (NIHB) program covers First Nations and Inuit peoples. Approximately 60% of Canadians have some form of private (employer-sponsored) drug insurance, creating a patchwork of coverage that leaves gaps, particularly for working-poor and self-employed Canadians. The Hoskins report of 2019 recommended universal single-payer pharmacare; this debate continues at the federal level, with the Canadian Pharmacists Association and other health organizations advocating for improved public drug coverage as a matter of health equity.

Provincial drug formularies determine which drugs are publicly funded and under what conditions. In Ontario, the Ontario Drug Benefit (ODB) Formulary is managed by the Ontario Public Drug Programs (OPDP) and covers thousands of drug products. New drugs are assessed for formulary listing by the Canadian Drug Policy Alliance’s reimbursement recommendations, informed by the Canadian Drug Agency (CDA, formerly CADTH — the Canadian Drug and Health Technology Agency), which conducts health technology assessments (HTAs) evaluating the clinical effectiveness, safety, and cost-effectiveness of new drugs for reimbursement decision-making in Canadian public drug plans. Understanding the formulary and reimbursement landscape is practically important for pharmacists, who help patients navigate prior authorization requirements, access special authorization programs for non-formulary drugs, and identify lower-cost alternatives when patients face coverage gaps.

The Pharmacists’ Patient Care Process

The Pharmacists’ Patient Care Process (PPCP) is a systematic, patient-centred framework for delivering pharmacy care adopted by NAPRA and pharmacy professional associations across Canada. It provides a structured approach to patient assessment and drug therapy management — a clinical reasoning framework — that situates pharmacy within the interprofessional healthcare team and makes the pharmacist’s cognitive work visible and legible to other team members.

The PPCP consists of five iterative steps. First, collecting: gathering subjective (symptoms, patient concerns, medication history, allergies, social history, health goals) and objective (vital signs, lab values, physical assessment) information relevant to the patient’s health concerns and drug therapy. Second, assessing: interpreting collected information to identify drug therapy problems — situations in which the patient’s drug therapy is not achieving therapeutic goals or is causing harm. Drug therapy problems include unnecessary drug therapy, untreated medical conditions, wrong drug, wrong dose (too high or too low), adverse drug reactions, drug interactions, and non-adherence. Third, planning: developing individualized recommendations for drug therapy changes, monitoring parameters, patient education, and follow-up, prioritized and tailored to the patient’s values, preferences, and circumstances. Fourth, implementing: communicating with the patient and other team members, executing agreed interventions, and documenting the clinical encounter in a manner that supports continuity of care and professional accountability. Fifth, following up: assessing outcomes, identifying new problems, and adjusting the care plan iteratively in an ongoing therapeutic relationship.

Chapter 10: Special Populations in Pharmacy

Pediatric Pharmacotherapy

Children are not simply small adults. The processes of drug absorption, distribution, metabolism, and excretion differ substantially between children and adults and evolve dramatically across the pediatric age spectrum — from the premature neonate to the adolescent. These pharmacokinetic differences, combined with the distinct pharmacodynamic sensitivities of the developing organ systems, make pediatric pharmacotherapy one of the most technically demanding areas of clinical pharmacy practice.

Gastric acid secretion at birth is low and reaches adult levels only by age 2-3 years; this affects the bioavailability of acid-labile drugs (e.g., ampicillin is better absorbed orally in neonates than in adults) and of drugs whose absorption is pH-dependent. Gastric emptying is slower in neonates and preterm infants, delaying the rate of drug absorption from the small intestine. The higher body water content of neonates (approximately 80% of body weight, vs. 60% in adults) leads to a larger volume of distribution for hydrophilic drugs such as aminoglycoside antibiotics, meaning that higher per-kilogram doses are needed to achieve therapeutic serum concentrations. Conversely, neonates have less adipose tissue, reducing the distribution volume and extending the half-life of lipophilic drugs.

Hepatic drug metabolism capacity is substantially lower in neonates and young infants than in adults, reflecting the immature expression of CYP enzymes and Phase II conjugating enzymes. CYP3A7 (the fetal isoform of CYP3A) is the predominant CYP3A enzyme in the fetal liver and gradually declines after birth, replaced by CYP3A4 and CYP3A5. CYP2D6 expression is very low at birth and reaches adult levels by 3-5 years. UGT enzymes responsible for glucuronidation are also immature in neonates, which is clinically illustrated by the “grey baby syndrome” caused by chloramphenicol: neonates cannot adequately glucuronidate chloramphenicol, leading to drug accumulation and cardiovascular collapse. The tragic 1950s cases of grey baby syndrome led to the recognition that drugs must be specifically studied in pediatric populations and that adult pharmacokinetics cannot simply be scaled to children by weight.

Geriatric Pharmacotherapy

The elderly — conventionally defined as those aged 65 years and older, though significant heterogeneity exists within this broad category — are the largest consumers of prescription medications in Canada and the group at highest risk for adverse drug reactions, drug-drug interactions, and drug therapy problems. The risk of adverse drug reactions increases roughly exponentially with the number of medications a patient takes (polypharmacy), and the elderly are disproportionately affected by polypharmacy: Canadian statistics indicate that approximately 60% of adults aged 65 and older take five or more medications, and a substantial proportion take ten or more.

Age-related changes in pharmacokinetics are pervasive and clinically consequential. Gastric acid secretion decreases with age, reducing the solubility of weakly basic drugs and potentially affecting the bioavailability of drugs that depend on acidic conditions for dissolution. Lean muscle mass declines with age while adipose tissue proportion often increases — this means that lipophilic drugs distribute into a larger fat compartment, increasing their V_d and prolonging their half-life, while hydrophilic drugs have a decreased V_d and potentially higher peak concentrations for a given dose. Albumin concentrations may decrease in frail or malnourished older adults, potentially increasing the free fraction of highly protein-bound drugs. Hepatic mass and blood flow decline with age, reducing the hepatic clearance of drugs with high extraction ratios (e.g., morphine, propranolol, lidocaine); CYP enzyme expression also declines modestly with age for some isoforms.

The most clinically important age-related pharmacokinetic change is the decline in glomerular filtration rate with aging — approximately 1% per year after age 40 in the absence of disease. By age 80, GFR is often reduced to 40-50% of young-adult values even in apparently healthy individuals, substantially reducing the renal clearance of drugs excreted by filtration. This makes renal function assessment and dose adjustment for renally-cleared drugs — antibiotics such as trimethoprim-sulfamethoxazole and nitrofurantoin, DOAC anticoagulants such as dabigatran and rivaroxaban, the antidiabetic agent metformin, digoxin, lithium, and many others — a critical routine component of geriatric pharmacy care. The Beers Criteria (developed by the American Geriatrics Society) and the STOPP/START criteria (validated in a European elderly population) provide evidence-based lists of medications that are potentially inappropriate in older adults and medications that are potentially under-prescribed relative to evidence-based guidelines, respectively; Canadian pharmacists use these tools as frameworks for identifying and resolving drug therapy problems in geriatric patients.

Pregnancy and Lactation Pharmacotherapy

Drug use in pregnancy presents unique challenges: both the pregnant patient’s welfare and the welfare of the developing fetus must be considered. Most drugs cross the placenta to some degree, and the developing fetal organ systems — particularly during organogenesis in the first trimester (weeks 3-8 of gestation, corresponding to gestational weeks 5-10) — are vulnerable to teratogenic effects. However, undertreating serious conditions in pregnancy (inadequately controlled epilepsy, asthma, depression, hypertension, infectious diseases, autoimmune disorders) also poses risks to both mother and fetus, and the pharmacist must help balance these competing considerations in the context of a risk-benefit discussion.

The old FDA pregnancy category system (A, B, C, D, X) was replaced in 2015 by narrative labeling in the Pregnancy, Lactation, and Reproductive Potential sections of drug prescribing information, providing more nuanced and clinically useful information. Health Canada’s product monographs similarly provide narrative description of available data. Key resources for pharmacists include the Motherisk Program (based at SickKids Hospital in Toronto until its closure in 2015, now distributed across provincial clinical programs), the TERIS database, and Lactmed (for lactation-specific information). The LactMed database, a free resource from the National Institutes of Health, provides peer-reviewed information on drug concentrations in breast milk, effects on breastfed infants, and guidance on whether breastfeeding should be continued.

Chapter 11: Drug Policy, Ethics, and Equity in Pharmacy

The Canadian Cannabis Framework

The Cannabis Act (Bill C-45), which came into force on October 17, 2018, legalized recreational cannabis for adults in Canada — making Canada only the second country in the world (after Uruguay) to federally legalize recreational cannabis. The Act establishes a federal framework for the production, distribution, and sale of cannabis, with provinces and territories responsible for determining the retail model. From a pharmacy practice perspective, the legalization of recreational cannabis has important implications: pharmacists are increasingly asked to counsel patients about therapeutic cannabis use, potential drug-drug interactions between cannabis and prescription medications, and the risks of cannabis use in vulnerable populations.

Cannabis contains over 100 cannabinoids; the most pharmacologically active are delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD). THC acts primarily as a partial agonist at CB1 receptors (predominantly in the central nervous system) and CB2 receptors (predominantly in the immune system and periphery), producing its psychoactive effects, analgesia, antiemesis, and appetite stimulation. CBD has complex pharmacology at multiple targets including TRP channels, GPR55, 5-HT1A receptors, and voltage-gated ion channels; it has demonstrated efficacy in specific childhood epilepsy syndromes (Epidiolex/Epidyolex is approved in Canada for Dravet syndrome and Lennox-Gastaut syndrome) and may have anti-inflammatory, anxiolytic, and analgesic properties, though the evidence base for most therapeutic cannabis claims outside epilepsy is limited.

Drug interactions with cannabis are a practical clinical concern. CBD is a potent inhibitor of CYP2C19 and a moderate inhibitor of CYP3A4 and CYP2C9 in vitro and in vivo. Clinically relevant interactions include: clobazam (a CYP2C19 substrate widely used in epilepsy) whose active N-desmethyl-clobazam metabolite accumulates significantly with CBD co-administration; warfarin, whose CYP2C9-mediated metabolism is inhibited by CBD, increasing anticoagulant effect; and other drugs metabolized by these enzymes. THC and CBD also inhibit P-glycoprotein (P-gp) and other efflux transporters, potentially increasing the bioavailability of P-gp substrate drugs. Pharmacists advising patients who use cannabis — recreational or medical — should specifically inquire about and evaluate potential drug interactions.

The Opioid Crisis — A Public Health Emergency

The ongoing opioid crisis has claimed tens of thousands of Canadian lives since 2016 through overdose deaths driven by the contamination of the illicit drug supply with illicitly manufactured fentanyl and fentanyl analogues (including carfentanil). British Columbia declared a public health emergency in April 2016; federal and provincial governments have responded with expanded access to naloxone, funding for harm reduction programs (supervised consumption sites, take-home naloxone, drug checking services), regulatory changes facilitating prescribing of pharmaceutical-grade opioids as substitutes for the toxic illicit supply, and expanded access to opioid agonist therapy (OAT) — methadone and buprenorphine-naloxone.

Pharmacists are on the front lines of this crisis in multiple indispensable roles. Naloxone, the opioid antagonist that rapidly reverses opioid overdose, is now available without prescription at pharmacies across Canada; pharmacists dispense naloxone kits and provide training to patients and caregivers on recognition of overdose and intranasal or IM naloxone administration. Pharmacists who dispense buprenorphine-naloxone (Suboxone and generics) provide witnessed ingestion or carries (take-home doses) under standardized provincial programs, monitor for signs of diversion or misuse, and engage in the therapeutic relationship that is central to OAT success. Methadone for OAT is dispensed exclusively in pharmacies in most Canadian provinces, with daily witnessed ingestion; the pharmacist’s daily contact with the patient provides a uniquely valuable opportunity to monitor for clinical deterioration, assess for drug interactions (methadone is a CYP3A4 substrate and prolongs the QTc interval), identify mental health concerns, and connect patients with additional supports.

Professional Ethics and Patient Autonomy

Pharmacy, like all health professions, operates within an ethical framework defining obligations to patients, colleagues, and society. The major ethical principles applied in healthcare — autonomy, beneficence, non-maleficence, and justice — provide a vocabulary and structure for reasoning through ethical dilemmas, though they rarely resolve dilemmas mechanically; ethical practice requires judgement, contextual sensitivity, and ongoing reflection.

Patient autonomy — the right of competent patients to make their own healthcare decisions — is central to contemporary pharmacy ethics. Respecting autonomy means providing accurate, complete, and balanced information about drug therapy in a manner patients can understand, without using professional authority to coerce or unduly influence their choices. The pharmacist who disagrees with a patient’s treatment choice (for example, a patient’s decision to discontinue an evidence-based medication because of side effects that the pharmacist considers manageable) must respect that decision while ensuring the patient understands the consequences and has the information needed to make a truly informed choice. This requires sophisticated communication skills and genuine humility about the limits of the pharmacist’s knowledge of the patient’s lived experience, values, and priorities.

Justice in pharmacy ethics encompasses not only the fair treatment of individual patients but the distribution of healthcare resources and the responsibility to address systemic barriers to equitable care. The pharmacist who understands the social determinants of health — income, education, housing, food security, social inclusion — is better positioned to provide truly patient-centred care, recognizing when a patient’s inability to afford medications requires not just advice to “take as directed” but active assistance in navigating drug benefit programs, generic substitution, manufacturer assistance programs, or formulary alternatives. Advocacy for policies that improve equitable access to medicines — expanded public drug coverage, reduced cost-sharing for low-income patients, elimination of prior authorization processes that create barriers for evidence-based therapies — is an expression of the justice principle and a professional responsibility for pharmacists working in the Canadian healthcare system.

Chapter 12: The Future of Pharmacy — Emerging Technologies and Practice Transformation

Artificial Intelligence in Drug Discovery and Clinical Practice

Artificial intelligence and machine learning are beginning to reshape multiple aspects of pharmaceutical science and pharmacy practice in ways that have significant implications for how pharmacists learn, practice, and add value to patient care. In drug discovery, AI systems trained on large datasets of molecular structures and their biological activities are being used to generate novel molecular hypotheses, predict binding affinity to targets, anticipate metabolic liabilities, and prioritize compounds for synthesis and biological testing. DeepMind’s AlphaFold and related protein structure prediction tools have effectively solved the decades-old problem of predicting protein three-dimensional structure from amino acid sequence — a foundational challenge for structure-based drug design — making computational target engagement analysis far more accessible than when it required experimentally determined crystal structures.

In clinical pharmacy, AI applications include clinical decision support systems embedded in electronic health records and pharmacy dispensing systems that flag potential drug interactions, contraindications, and dosing errors in real time. Machine learning algorithms trained on large electronic health record datasets can identify patients at high risk of adverse drug reactions, medication non-adherence, clinical deterioration, or hospital readmission — information that can trigger proactive pharmacist interventions. Natural language processing (NLP) tools extract structured clinical information from free-text medical records, supporting medication reconciliation, drug therapy review, and regulatory pharmacovigilance. The integration of AI with point-of-care diagnostics — continuous glucose monitoring, smartwatch electrocardiography, digital stethoscopes — is expanding the pharmacist’s ability to perform comprehensive clinical assessments in community settings.

The critical evaluation of AI tools is itself becoming a pharmacy competency. AI systems reflect the data on which they are trained, and if training data embeds historical biases — if clinical trial populations systematically under-represent women, elderly patients, or racialized groups, which is well documented in pharmaceutical research — AI predictions will be less accurate for these populations. The “explainability” of AI recommendations is essential for pharmacist accountability: a pharmacist cannot responsibly act on a recommendation they cannot evaluate for clinical plausibility, and “black box” algorithms that produce recommendations without transparent reasoning cannot substitute for professional judgment. The regulatory framework for AI-enabled clinical decision support in Canada is actively developing, with Health Canada’s Digital Health Centre of Excellence working on guidance for software as a medical device (SaMD) that includes AI components.

Gene and Cell Therapies

Gene and cell therapies represent the most transformative emerging category of medical intervention, with the potential to cure diseases that were previously incurable and to address the root genetic or immunological causes of disease rather than merely managing its symptoms. Several gene and cell therapies have already received regulatory approval in Canada and internationally, and many more are in clinical development.

Chimeric antigen receptor T cell (CAR-T) therapies — in which a patient’s own T lymphocytes are harvested, genetically engineered to express an artificial T cell receptor that recognizes cancer cell surface antigens (most commonly CD19 on B cell malignancies), and re-infused into the patient — have produced remarkable responses in relapsed or refractory B cell lymphomas, multiple myeloma, and acute lymphoblastic leukemia, including durable remissions in patients for whom all other treatments had failed. In Canada, tisagenlecleucel (Kymriah), axicabtagene ciloleucel (Yescarta), and lisocabtagene maraleucel (Breyanzi) are approved for various B cell malignancies. The management of CAR-T therapy requires specialized pharmacy expertise in these biological products, their complex cold chain logistics, and their potentially severe adverse effects including cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS).

Pharmacy’s Evolving Scope in Canada

The scope of pharmacy practice in Canada will continue to expand in the coming decade, driven by evidence of pharmacist effectiveness, healthcare system capacity pressures, and the growing recognition that pharmacists are an underutilized resource in the primary care ecosystem. Minor ailment prescribing — already implemented in Ontario, Alberta, British Columbia, New Brunswick, and Nova Scotia with varying lists of conditions — is expected to expand nationally as evidence accumulates that pharmacist prescribing for minor ailments is safe, effective, patient-satisfying, and cost-saving. The Ontario model, which authorizes pharmacists to prescribe for 19 minor ailments including urinary tract infections, skin conditions, smoking cessation, and others (with more conditions added over time), represents a substantial practice expansion that is being watched and emulated by other provinces.

Collaborative practice agreements, professional service agreements, and integrated models of primary care (in which pharmacists are embedded in family health teams, community health centres, and other primary care settings) create opportunities for deeper pharmacist engagement in chronic disease management — diabetes, hypertension, dyslipidemia, mental health — where medication optimization is the primary lever for improving outcomes. The evidence base for pharmacist-led interventions in these conditions is substantial: systematic reviews consistently show that pharmacist involvement in collaborative care improves blood pressure control, glycemic control, medication adherence, and a range of other outcomes. Translating this evidence into sustainable funding models and healthcare system structures that appropriately recognize and compensate pharmacist clinical services is the central advocacy challenge facing the pharmacy profession in Canada today.

As you progress through the PharmD program, every course you take — in therapeutics, pharmaceutical sciences, drug information, patient communication, professional practice, and clinical rotations — contributes to preparing you for this expanding and evolving professional role. PHARM 150 is the beginning of that journey: an introduction to the full arc from drug discovery to patient care, and an invitation to understand pharmacy not merely as a job but as a profession with a distinctive knowledge base, a profound societal responsibility, and an extraordinary opportunity to contribute to the health and wellbeing of the patients and communities you will serve.

Chapter 13: Drug Formulation, Routes of Administration, and Delivery Systems

Principles of Drug Formulation

Drug formulation is the science and engineering of transforming an active pharmaceutical ingredient (API) into a dosage form suitable for administration to a patient. The formulation must achieve four principal objectives: it must deliver the drug to the site of action at concentrations sufficient to produce a therapeutic effect; it must do so reliably and reproducibly from dose to dose; it must protect the drug from degradation during storage and in the body until it reaches the site of absorption; and it must be acceptable to patients in terms of appearance, taste, ease of administration, and tolerability. Achieving all of these objectives simultaneously requires deep knowledge of the physicochemical properties of the drug molecule — its solubility, stability, permeability, ionization, hygroscopicity — as well as of the biology of the route of administration and the clinical needs of the patient population.

The pharmaceutical development of a new drug formulation begins with preformulation studies, in which the physicochemical properties of the API are systematically characterized: solubility in aqueous and organic media, rate of dissolution from crystalline powder, melting point and polymorphic behavior (different crystalline forms of the same compound can have dramatically different solubility and bioavailability), pKa (the ionization constant, which determines what fraction of the drug is ionized or unionized at various pH values), lipophilicity (log P or log D), photostability, and hygroscopicity. Polymorphism — the ability of a compound to exist in multiple distinct crystalline forms with different physical properties — is a critically important preformulation consideration; the development history of ritonavir (an HIV protease inhibitor) includes a dramatic example of formulation failure caused by the spontaneous appearance of a new, less soluble polymorph (Form II) during manufacturing scale-up, which reduced bioavailability to approximately 25% of the original formulation and required an emergency reformulation using a solid dispersion in polyethylene glycol.

Excipients — the inactive ingredients in a drug product — serve multiple functions: diluents add bulk to make a small drug dose into a manageable tablet size; binders hold tablet components together; disintegrants promote tablet break-up in the gastrointestinal fluid; lubricants prevent adhesion to tablet punches during compression; coatings protect tablets from moisture, light, or gastrointestinal acid, or modify drug release; and preservatives prevent microbial contamination in multi-dose liquid preparations. Though called “inactive,” excipients are not pharmacologically inert — they can affect bioavailability (talc, magnesium stearate at high concentrations can retard tablet disintegration), cause allergic reactions (lactose in lactose-intolerant individuals; tartrazine [FD&C Yellow No. 5] in aspirin-sensitive asthmatics; benzalkonium chloride in inhaler formulations can cause bronchoconstriction), and interact with the API chemically. Regulatory requirements for excipient safety data are increasingly stringent, and pediatric formulation development must carefully consider that excipients safe in adults may be unsafe in neonates and infants — propylene glycol, used as a solvent in many injectable formulations, can accumulate to toxic levels in neonates; benzyl alcohol, used as a preservative, caused the “gasping syndrome” in premature neonates in the 1980s.

Modified-Release Formulations

Conventional immediate-release (IR) formulations release drug rapidly after administration, producing a rapid rise in plasma concentration, a peak, and then a decline over hours. For drugs with short biological half-lives, this concentration profile means that maintaining therapeutic drug concentrations requires frequent dosing — potentially three or four times daily — which is inconvenient, reduces adherence, and produces peaks and troughs that may produce alternating toxicity (at peak) and therapeutic inadequacy (at trough). Modified-release formulations alter the kinetics of drug release from the dosage form to achieve more desirable concentration-time profiles.

Extended-release (ER, XL, SR, XR — the nomenclature is not standardized across manufacturers) formulations slow drug release to maintain therapeutic drug concentrations over a longer period, typically allowing once-daily or twice-daily dosing. Several technologies achieve this: hydrophilic matrix tablets, in which the drug is embedded in a swelling polymer (typically hydroxypropyl methylcellulose, HPMC) that forms a gel layer in the presence of water through which drug diffuses slowly; reservoir membrane systems, in which the drug is surrounded by a semi-permeable polymer membrane that controls the rate of drug release; osmotic systems (such as the OROS system used in nifedipine GITS and some extended-release metformin products), in which water is driven into an osmotic compartment by osmotic pressure, pushing drug through a laser-drilled orifice at a controlled rate; and multiparticulate systems, in which drug is coated onto small pellets with controlled-release polymer coatings that are then filled into capsules. Extended-release formulations are not interchangeable with the corresponding immediate-release formulations and must be clearly identified in dispensing and reconciliation.

Enteric-coated (EC) formulations are designed to resist dissolution in the acidic environment of the stomach (pH 1-3) and to dissolve in the more neutral pH of the small intestine (pH 6-7.4). Enteric coatings are used for two distinct purposes: to protect acid-labile drugs from gastric acid degradation (e.g., omeprazole, pantoprazole, and other PPIs, which are acid-labile prodrugs that must reach the proximal small intestine intact to be absorbed and activated); and to protect the gastric mucosa from drug-induced injury (e.g., enteric-coated aspirin and enteric-coated naproxen, which deliver the drug to the intestine rather than the stomach to reduce direct mucosal contact, though they do not eliminate the systemic prostaglandin-mediated mucosal injury that is the primary mechanism of NSAID gastropathy). A critical counselling point is that enteric-coated tablets must not be crushed or chewed — crushing destroys the coating and negates its purpose. Many patients and caregivers assume that tablets can always be crushed for administration via feeding tube or for patients who cannot swallow; pharmacists must identify which formulations must not be altered and provide safe alternatives.

Parenteral Drug Delivery and Injectables

Parenteral administration — from the Greek meaning “beside the gut” — refers to any route that bypasses the gastrointestinal tract, typically through injection or infusion. The major parenteral routes are intravenous (IV), intramuscular (IM), subcutaneous (SC or SQ), intradermal (ID), and intrathecal (IT, into the cerebrospinal fluid). Each has distinct pharmacokinetic implications, administration requirements, and clinical indications.

Intravenous administration achieves 100% bioavailability by definition, delivers drug to the systemic circulation immediately, and allows precise control of plasma concentrations through rate-controlled infusion. IV formulations must meet exacting standards for sterility, particulate contamination, pH, and osmolality — they are injected directly into the bloodstream where errors in preparation or formulation can cause immediate, serious, and potentially lethal harm. The preparation of IV medications in the pharmacy — compounding sterile preparations in a cleanroom environment — is among the highest-risk and most technically demanding pharmacy activities. In Canada, standards for sterile compounding are governed by provincial pharmacy regulatory college standards and by Health Canada’s Good Manufacturing Practices (GMP) guidance; hospital pharmacies typically prepare IV admixtures, chemotherapy doses, total parenteral nutrition solutions, and other sterile products in laminar airflow workbenches or isolators within a classified cleanroom suite.

Intramuscular and subcutaneous injections achieve absorption through the rich capillary networks in muscle and subcutaneous tissue, respectively. IM absorption is generally faster than SC absorption because muscle is more vascularized; SC administration is the route of choice for many biologics (insulin, low molecular weight heparins, monoclonal antibodies) where sustained absorption over hours is desired. Long-acting injectable (LAI) antipsychotics — such as paliperidone palmitate (Invega Sustenna, monthly; Invega Trinza, quarterly), aripiprazole lauroxil (Aristada), and risperidone microspheres (Risperdal Consta) — are formulated as IM depot preparations that release drug slowly over weeks to months, providing continuous antipsychotic coverage without daily oral dosing and eliminating adherence uncertainty in patients who may not reliably take oral medications. The pharmacist’s role in LAI dispensing includes educating patients and care team members about injection schedules, monitoring for missed doses, and managing the pharmacokinetic tail (continuing oral supplementation during the initial loading period, recognizing that drug will continue to be absorbed for weeks after the last injection if discontinued).

Inhaled Drug Delivery

The lung is an extraordinary site for drug absorption — its surface area (approximately 70-140 m²), thin alveolar epithelium (0.2-0.5 μm), rich blood supply (the entire cardiac output passes through the pulmonary circulation every minute), and absence of first-pass metabolism make it highly efficient for drug absorption. Inhaled drug delivery serves two distinct purposes: local delivery of drug to the airways (bronchodilators, inhaled corticosteroids, inhaled antibiotics) to achieve high local concentrations with minimal systemic exposure and toxicity; and systemic delivery of drugs that cannot be given orally (inhaled insulin, though this has had limited commercial success, is one example; inhaled biologics are an active area of research).

The three major inhaled drug delivery devices used clinically are pressurized metered-dose inhalers (pMDIs), dry powder inhalers (DPIs), and nebulizers. pMDIs consist of a pressurized canister containing drug dissolved or suspended in a propellant (currently hydrofluoroalkane [HFA] propellants, replacing the older chlorofluorocarbons [CFCs] that were phased out under the Montreal Protocol), a metering valve that delivers a precisely controlled volume per actuation, and an actuator mouthpiece. The critical technical challenge of pMDI use is hand-breath coordination — the patient must simultaneously depress the canister and begin a slow, deep inhalation; failure to coordinate results in drug deposition in the oropharynx rather than the lower airways. Spacer devices (valved holding chambers) interpose a reservoir between the pMDI and the mouth, slowing the aerosol plume, reducing particle velocity, allowing larger particles to settle out, and virtually eliminating the coordination requirement — making them strongly recommended for all patients, particularly children and the elderly, and mandatory for inhaled corticosteroids to minimize oropharyngeal deposition and candidiasis risk.

Chapter 14: The Canadian Regulatory Framework — Health Canada and Drug Approval

Health Canada and the Therapeutic Products Directorate

In Canada, all pharmaceutical drugs intended for human use are regulated under the Food and Drugs Act (FDA) and its associated regulations, principally the Food and Drug Regulations. The federal department responsible for drug regulation is Health Canada, specifically through the Health Products and Food Branch (HPFB) and its Therapeutic Products Directorate (TPD) for pharmaceutical drugs and the Biologics and Genetic Therapies Directorate (BGTD) for biologics. The regulatory framework governing drugs in Canada has a comprehensive dual mandate: to protect Canadians from unsafe or ineffective drugs, and to enable timely access to beneficial new therapies by efficient review of evidence of quality, safety, and efficacy.

The regulatory pathway for a new drug in Canada begins with the submission of a Clinical Trial Application (CTA) to Health Canada, which authorizes the manufacturer to conduct clinical trials in Canada. The CTA must include preclinical data from pharmacological, pharmacokinetic, and toxicological studies in animals and in vitro systems, manufacturing information (chemistry and manufacturing controls, or CMC), and a detailed clinical trial protocol. Health Canada reviews the CTA and, if satisfied that the proposed trial can be conducted safely, issues authorization; if no objection is received within 30 days, the CTA is deemed approved and the trial may begin. This implies-consent approach is designed to facilitate timely trial start without sacrificing safety review.

Following successful Phase I, II, and III clinical trials, the manufacturer submits a New Drug Submission (NDS) to Health Canada. The NDS is a comprehensive package of data demonstrating the quality (pharmaceutical manufacturing and quality control), safety (preclinical toxicology and adverse event data from clinical trials), and efficacy (clinical trial results demonstrating the drug produces the claimed therapeutic effect) of the new drug. The Health Canada review process evaluates all three pillars of evidence and, if satisfied, issues a Notice of Compliance (NOC) — the Canadian equivalent of FDA drug approval — authorizing the drug to be marketed in Canada under the conditions specified in the product monograph. The product monograph (PM) is the official reference document for the approved drug — equivalent to the FDA-approved label — and specifies the approved indication(s), dosage regimen, contraindications, warnings and precautions, adverse reactions, drug interactions, pharmacology, and clinical study summaries.

Post-Market Surveillance and Pharmacovigilance

Drug regulation does not end at approval. The clinical trial data package submitted in an NDS, while extensive, has inherent limitations: trials typically enroll thousands of patients, insufficient to detect adverse effects occurring in fewer than 1 in 1,000 or 1 in 10,000 patients; trial populations are highly selected and may not represent the full diversity of patients who will eventually use the drug (elderly patients, children, pregnant women, and those with multiple comorbidities are often excluded from pivotal trials); the trial duration is limited and cannot capture adverse effects that take years to develop; and the trial conditions (protocol-mandated monitoring, selected investigator sites) do not fully reflect real-world prescribing. Post-market surveillance (pharmacovigilance) is therefore a critical and mandated component of the drug regulatory lifecycle.

Health Canada’s Canada Vigilance Program collects and analyzes spontaneous adverse drug reaction (ADR) reports from healthcare professionals, patients, and the pharmaceutical industry. Health Canada provides the Canada Vigilance Online Reporting Tool for electronic reporting, and the MedEffect Canada initiative promotes ADR reporting awareness among healthcare professionals. Pharmacists, as the most accessible healthcare professionals, are uniquely positioned to detect, document, and report ADRs — and the pharmacist’s systematic clinical review of medication regimens creates opportunities to identify ADRs that might otherwise be attributed to disease progression or under-reported. The WHO-UMC VigiBase international pharmacovigilance database — to which Health Canada contributes Canadian ADR data — contains over 30 million reports from 130 member countries and is the world’s largest database of reported adverse drug reactions, supporting signal detection analyses that have contributed to numerous regulatory actions.

When a post-market safety signal is confirmed, Health Canada’s regulatory response options include: adding new safety information to the product monograph (warnings, contraindications, precautions); issuing a Dear Healthcare Professional (DHCP) letter to alert prescribers and pharmacists; requiring risk minimization measures or a Risk Management Plan (RMP); restricting the approved indication or prescribing conditions; or, in the most serious cases, withdrawing the drug from the market. The withdrawal of rofecoxib (Vioxx) from the Canadian and global market in September 2004 — following the demonstration in the APPROVe trial that the COX-2 selective NSAID doubled the risk of myocardial infarction and stroke compared to placebo — is one of the most significant post-market safety actions in pharmaceutical history, ultimately affecting tens of millions of patients worldwide and profoundly shaping regulatory expectations for cardiovascular safety assessment of analgesic and anti-inflammatory drugs.

Controlled Substances — The CDSA and Cannabis Act

Drugs with significant abuse potential and that pose risks of dependence or misuse are regulated in Canada under the Controlled Drugs and Substances Act (CDSA), which divides controlled substances into eight Schedules based on their pharmacological properties and risk profiles. Schedule I substances (heroin, cocaine, PCP, and their derivatives) have high abuse potential, no accepted medical use in Canada, and are prohibited. Schedule II (cannabis and its derivatives, prior to the Cannabis Act) is now regulated under the separate Cannabis Act (see Chapter 11). Schedule III includes amphetamines and methamphetamine. Schedule IV includes benzodiazepines, barbiturates, and anabolic steroids — substances with accepted medical uses but also significant abuse potential. Schedule V includes phencyclidine (PCP) precursors. Narcotics — including opioids such as morphine, codeine above 8 mg/unit, fentanyl, oxycodone, and methadone — are regulated under Part J of the Food and Drug Regulations and the Narcotic Control Regulations.

For pharmacists, the most practically important aspects of CDSA regulation are the record-keeping, dispensing, and inventory requirements for narcotics and controlled drugs. Prescriptions for narcotics must meet specific requirements: they must be written in ink, signed by the prescriber, include the patient’s name and address, the drug name and quantity, and they may not be prescribed for the prescriber themselves or for members of the prescriber’s immediate family (with limited exceptions). Some provinces require the use of triplicate or tamper-evident prescription forms (e.g., the Ontario Prescription Drug Monitoring Program’s Narcotics Safety and Awareness Act requirements). Pharmacies must maintain physical count records for narcotics, report discrepancies to Health Canada’s Office of Controlled Substances, and maintain records available for inspection. The National Drug Scheduling System (NDSS) managed by NAPRA provides a complementary classification system — Schedule I (prescription only), Schedule II (behind the pharmacy counter, pharmacist counselling required), Schedule III (in the pharmacy, self-selection permitted but pharmacist available), and Unscheduled (any retail outlet) — that governs access to drugs in terms of professional oversight, independent of the CDSA’s abuse-potential-based classification.

Chapter 15: Pharmacogenomics — Individualizing Drug Therapy

Foundations of Pharmacogenomics

Pharmacogenomics is the study of how an individual’s genetic makeup influences their response to drugs — including pharmacokinetic differences in how drugs are absorbed, distributed, metabolized, and excreted, and pharmacodynamic differences in how drug targets respond to drug binding. The ambition of pharmacogenomics is to transform drug prescribing from a “one-dose-fits-all” approach to a precision medicine model in which genetic information guides individualized drug and dose selection to maximize therapeutic benefit while minimizing the risk of adverse drug reactions.

The pharmacogenomic variation most consequential for current clinical practice concerns the cytochrome P450 enzymes — particularly CYP2D6, CYP2C9, CYP2C19, and CYP3A5 — which together metabolize approximately 40-50% of all drugs. These enzymes display extensive genetic polymorphism in the human population, with many functionally distinct alleles that encode enzyme variants with reduced, absent, or enhanced activity. For CYP2D6, the major phenotypic categories are poor metabolizers (PMs, who carry two non-functional alleles and have no CYP2D6 activity), intermediate metabolizers (IMs, who have one functional and one reduced-function or non-functional allele), extensive/normal metabolizers (EMs, who have two functional alleles and represent the most common phenotype in most populations), and ultra-rapid metabolizers (UMs, who have gene duplications resulting in supernormal CYP2D6 activity). The clinical consequences of these phenotypic differences are significant: CYP2D6 PMs taking codeine (a prodrug that requires CYP2D6-mediated conversion to morphine for analgesic activity) experience no pain relief because they cannot generate morphine; CYP2D6 UMs taking codeine generate dangerous morphine concentrations because their very high CYP2D6 activity converts codeine to morphine more rapidly than the normal population. Health Canada and the FDA have both added warnings to codeine product monographs regarding these pharmacogenomic risks; Health Canada has restricted codeine use in children under 12 and in breastfeeding women (where the infant may be exposed to high morphine concentrations in breast milk if the mother is a UM) for this reason.

Clinically Actionable Pharmacogenomic Pairs

The Clinical Pharmacogenomics Implementation Consortium (CPIC) is an international collaboration of pharmacogenomics experts, clinical pharmacologists, and genetics professionals that develops and maintains evidence-based clinical practice guidelines for pharmacogenomically-guided drug prescribing. CPIC guidelines are organized by gene-drug pairs — specific combinations of pharmacogenomic gene and drug for which there is sufficient evidence to support genotype-guided prescribing — and are graded by the strength of the pharmacogenomic recommendation: Level A recommendations indicate that genetic information should be used to change prescribing; Level B recommendations indicate that genetic information could be used to change prescribing; Level C and D recommendations indicate insufficient evidence for routine action.

CYP2C19 and clopidogrel is among the most clinically important and best-characterized CPIC gene-drug pairs. Clopidogrel is a prodrug that requires bioactivation by CYP2C19 and, to a lesser extent, other CYP enzymes to generate its active thiol metabolite, which irreversibly inhibits the platelet P2Y12 ADP receptor and prevents platelet aggregation. CYP2C19 loss-of-function alleles (*2 and *3 are the most common) reduce clopidogrel bioactivation and produce “clopidogrel resistance” — reduced platelet inhibition, lower active metabolite concentrations, and, in retrospective analyses of large clinical datasets, higher rates of major adverse cardiovascular events (MACE) including stent thrombosis, myocardial infarction, and stroke compared to CYP2C19 EMs. Approximately 25-35% of patients of European ancestry and 50-60% of patients of East Asian ancestry carry at least one CYP2C19 loss-of-function allele. CPIC Level A guidance recommends that CYP2C19 IMs and PMs receiving clopidogrel after percutaneous coronary intervention (PCI) be switched to prasugrel or ticagrelor — potent antiplatelet agents that do not require CYP2C19 bioactivation — unless contraindicated (prasugrel is contraindicated in patients with history of stroke/TIA, and in patients above 75 years of age or below 60 kg body weight due to bleeding risk).

HLA-associated idiosyncratic hypersensitivity reactions represent a second critical category of pharmacogenomic interaction. Human leukocyte antigens (HLAs) are cell surface proteins that present peptide antigens to T lymphocytes; their extraordinary polymorphism (tens of thousands of alleles at each of the HLA loci) reflects their biological role in immune surveillance. Some drug-HLA allele combinations cause severe T-lymphocyte-mediated hypersensitivity reactions by a mechanism in which the drug binds to the HLA-peptide-TCR complex and directly activates T cells, producing massive cytokine release. HLA-B57:01 strongly predicts abacavir hypersensitivity syndrome — a severe systemic hypersensitivity reaction occurring in approximately 5-8% of unscreened patients initiated on abacavir (a nucleoside reverse transcriptase inhibitor used in HIV treatment), characterized by fever, rash, gastrointestinal symptoms, and respiratory symptoms that progress rapidly and can be fatal if rechallenge occurs. The PREDICT-1 randomized trial demonstrated that prospective HLA-B57:01 screening before abacavir prescribing virtually eliminated the immunologically confirmed hypersensitivity syndrome; this finding led to HLA-B57:01 screening becoming the standard of care before abacavir prescribing in Canada, the US, Australia, and Europe. Health Canada’s product monograph for abacavir-containing products (Ziagen, Kivexa/Epzicom, Triumeq) includes a boxed warning and requirement for HLA-B57:01 screening.

Implementation of Pharmacogenomics in Canadian Practice

Despite the scientific advances in pharmacogenomics, implementation in routine Canadian clinical practice remains incomplete. Barriers to implementation include: the cost of genotyping (though panels covering multiple clinically actionable genes for several hundred dollars are now available, and costs are declining rapidly with next-generation sequencing technologies); the lack of universal coverage by provincial drug benefit programs for pharmacogenomic testing (some tests are covered; others require out-of-pocket payment or are available only in academic centres); the limited integration of pharmacogenomic test results into electronic health records in ways that make them actionable at the point of prescribing; insufficient pharmacogenomics education in many healthcare provider training programs; and the complexity of interpreting pharmacogenomic results in the context of drug interactions, which can phenoconvert a patient’s genotypic EM status to functional PM status (e.g., a CYP2D6 EM taking fluoxetine, a potent CYP2D6 inhibitor, will have markedly reduced CYP2D6 activity and behave pharmacokinetically like a PM).

Pharmacists are ideally positioned to be the clinical pharmacogenomics champions in healthcare teams. No other health professional has deeper knowledge of drug metabolism, drug interactions, and the mechanistic basis of adverse drug reactions. In institutions and practices where pharmacogenomic testing is available, pharmacists can recommend appropriate testing, interpret results in the context of the patient’s complete medication list, translate genotype results into phenotype predictions, and provide specific, actionable prescribing recommendations to prescribers. Community pharmacies offering pharmacogenomic testing services — using point-of-care buccal swab sampling and rapid-turnaround laboratory analysis — are an emerging practice model that extends pharmacogenomic assessment to ambulatory patients who are not connected to academic health centres. As pharmacogenomics moves into mainstream clinical practice over the next decade, the pharmacist’s role as the expert integrator of genetic and pharmacological information will be central to realizing the promise of precision medicine.

Chapter 16: Biopharmaceuticals, Biosimilars, and Advanced Therapeutics

Structure and Pharmacology of Biopharmaceuticals

Biopharmaceuticals — drugs derived from or produced in living biological systems — represent the fastest-growing segment of the pharmaceutical market and include some of the most effective and innovative therapies of the past three decades. Unlike small-molecule drugs, which are chemically synthesized and typically have molecular weights below 1,000 Daltons and well-defined chemical structures, biopharmaceuticals are produced by genetically engineered cells or organisms, have complex, high-molecular-weight structures (monoclonal antibodies have molecular weights of approximately 150,000 Daltons), and exhibit structural heterogeneity arising from post-translational modifications (glycosylation, folding patterns, disulfide bond arrangements) that depend on the specific production cell line and manufacturing process.

Therapeutic proteins represent the broadest category of biopharmaceuticals and include recombinant versions of human proteins that are deficient or absent in patients with specific diseases. Recombinant human insulin — the first biopharmaceutical to receive regulatory approval (FDA, 1982; Health Canada followed) — replaced the porcine and bovine insulin preparations that had been used since the 1920s, eliminating immunogenicity concerns and enabling the production of insulin analogs with engineered pharmacokinetic profiles. Insulin lispro (Humalog), insulin aspart (NovoRapid), and insulin glulisine (Apidra) are rapid-acting analogs produced by replacing or swapping specific amino acids in the insulin B chain to disrupt the tendency of regular insulin to self-associate as hexamers; the monomeric analogs are absorbed more rapidly after SC injection and begin acting within 15 minutes, matching the postprandial glycemic excursion more effectively than regular insulin. Basal insulin analogs — insulin glargine (Lantus, Basaglar, Toujeo) and insulin degludec (Tresiba) — have modifications that shift the isoelectric point or create fatty acid extensions that cause formation of subcutaneous microprecipitates or self-assembled multimers after injection, slowing absorption and extending duration of action to 24 hours (glargine) or beyond 42 hours (degludec).

Monoclonal antibodies (mAbs) are the dominant class of biopharmaceuticals by both therapeutic impact and market share. Produced by hybridoma technology (Köhler and Milstein, 1975 — Nobel Prize 1984) or, increasingly, by phage display and other recombinant techniques, mAbs are immunoglobulin G (IgG) molecules engineered to bind with high affinity and selectivity to specific molecular targets — disease-relevant antigens, cytokines, growth factor receptors, or cell surface proteins. The naming conventions for mAbs encode information about their origin and target: murine antibodies end in -omab (e.g., tositumomab); chimeric antibodies (human constant regions, murine variable regions) end in -ximab (e.g., infliximab, rituximab); humanized antibodies (human framework regions with murine complementarity-determining regions) end in -zumab (e.g., trastuzumab, bevacizumab); fully human antibodies end in -umab (e.g., adalimumab, pembrolizumab). The degree of humanization influences immunogenicity — fully human antibodies are generally less immunogenic than chimeric antibodies, though the specific antigen-binding region can still be immunogenic regardless of overall antibody humanization.

Biosimilars — Regulation and Interchangeability in Canada

A biosimilar is a biopharmaceutical that is highly similar to an already-approved reference biopharmaceutical (the innovator or originator product) in terms of structure, biological activity, pharmacokinetics, and clinical safety and efficacy, but that is not identical because the complex manufacturing process of biopharmaceuticals cannot be replicated exactly. The regulatory pathway for biosimilars in Canada is distinct from the generic drug pathway — biosimilars cannot be approved on the basis of pharmacokinetic bioequivalence alone (as small-molecule generics can), because structural similarity and bioequivalence do not guarantee clinical equivalence for the complex molecules involved. Health Canada’s Guidance on Subsequent Entry Biologics (SEBs) — Canada’s term for biosimilars — requires a comprehensive comparability exercise demonstrating molecular and functional similarity (analytical characterization, biological assays, pharmacokinetic/pharmacodynamic studies, and in most cases at least one adequately powered clinical study demonstrating comparable efficacy, safety, and immunogenicity).

The advent of biosimilar competition has dramatically reduced the cost of biopharmaceuticals in therapeutic categories where biosimilars are available. Infliximab biosimilars (Inflectra, Renflexis, Avsola, and others) have achieved price discounts of 20-40% compared to the originator Remicade in Canadian formularies; adalimumab biosimilars (Hadlima, Hulio, Hyrimoz, and others) have similarly reduced the cost of the world’s best-selling drug in jurisdictions where they are approved and widely adopted. For public drug programs managing formulary costs, biosimilar uptake is a major cost-reduction lever; for pharmacy practice, biosimilar expertise — including knowledge of which biosimilars are approved for which indications, how to counsel patients on transitions, how to monitor for any clinical differences, and how to document and report any adverse events — is becoming an essential competency.

Chapter 17: Special Topics in Pharmacology — Immunopharmacology and Oncology

The Immune System as a Drug Target

Immunopharmacology — the pharmacological modulation of immune function — has become one of the most productive and rapidly evolving areas of pharmaceutical science, producing drug classes that are profoundly changing the treatment of autoimmune diseases, inflammatory conditions, transplant rejection, and cancer. The immune system is extraordinarily complex — a multilayered network of cell types, cytokines, surface receptors, and signaling pathways with interconnected regulatory mechanisms — and its dysfunction underlies a vast range of human diseases, making it both a high-value therapeutic target and a challenging one to modulate without disrupting the protective immunity essential for host defense.

Cytokine-targeted therapies represent the most clinically successful class of immunomodulatory biopharmaceuticals. Cytokines — including interleukins (ILs), tumor necrosis factors (TNFs), interferons, and colony-stimulating factors — are small signaling proteins secreted by immune cells that coordinate the immune response by regulating cell proliferation, differentiation, migration, and effector function. In autoimmune and inflammatory diseases such as rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, inflammatory bowel disease, and psoriasis, the immune response is chronically dysregulated, with overproduction of pro-inflammatory cytokines such as TNF-α, IL-6, IL-12/23, and IL-17A driving tissue inflammation and destruction. TNF inhibitors — adalimumab (Humira), infliximab (Remicade), etanercept (Enbrel), certolizumab pegol (Cimzia), golimumab (Simponi) — neutralize TNF-α and have transformed the treatment of these conditions, enabling remission in patients who had failed conventional disease-modifying antirheumatic drugs (DMARDs). The IL-6 receptor antagonists (tocilizumab, sarilumab), IL-12/23 antagonists (ustekinumab), IL-17A antagonists (secukinumab, ixekizumab), and IL-23 antagonists (guselkumab, risankizumab) have added additional precision to biologic selection, allowing therapies to be matched to the specific cytokine pathways most relevant to a patient’s disease phenotype.

Immunosuppression in Solid Organ Transplantation

Solid organ transplantation has transformed the prognosis of patients with end-stage organ failure — kidney, liver, heart, lung, pancreas — but requires permanent immunosuppression to prevent immune-mediated rejection of the transplanted organ. The immunosuppressive regimens used in transplantation are among the most complex and pharmacokinetically demanding in clinical medicine, combining drugs with narrow therapeutic indices, extensive drug interactions, and organ toxicity profiles that can ironically damage the very organ being protected. The pharmacist’s role in transplant management — dose optimization, drug interaction management, therapeutic drug monitoring, adverse effect monitoring, patient education, and medication reconciliation — is extensive and indispensable.

The standard triple immunosuppressive regimen after solid organ transplantation typically includes: a calcineurin inhibitor (tacrolimus or cyclosporine), an antiproliferative agent (mycophenolate mofetil [MMF] or azathioprine), and a corticosteroid (prednisone, tapered and often discontinued after the first post-transplant year). Tacrolimus inhibits the phosphatase calcineurin, which activates the transcription factor NFAT; by inhibiting calcineurin, tacrolimus prevents NFAT-mediated transcription of IL-2, the primary T-cell growth factor, suppressing T-cell proliferation and activation. Tacrolimus is a CYP3A4 substrate and is also transported by P-glycoprotein; its narrow therapeutic index (trough concentrations 5-20 ng/mL for kidney transplant, adjusted by time post-transplant and rejection risk) and extensive pharmacokinetic variability make therapeutic drug monitoring mandatory, and the drug interaction profile of tacrolimus is among the most complex in clinical pharmacology. Azole antifungals (fluconazole, voriconazole, itraconazole) — which are CYP3A4 inhibitors and are commonly used in transplant recipients at high risk of fungal infection — dramatically increase tacrolimus concentrations and require dose reductions of 50-75% or more; failure to anticipate and manage this interaction can result in tacrolimus toxicity (nephrotoxicity, neurotoxicity, hyperkalemia, hypertension). Rifampin — a potent CYP3A4 inducer used for treatment of tuberculosis and mycobacterial infections, to which immunocompromised patients are at increased risk — reduces tacrolimus concentrations by 80-90%, potentially precipitating acute rejection; the combination requires extreme dose escalation and intensive monitoring.

Oncology Pharmacology — Mechanisms of Anti-Cancer Drugs

Cancer pharmacology has undergone a revolution in the past two decades, driven by the molecular characterization of cancer driver mutations and the development of targeted therapies and immune checkpoint inhibitors that exploit the specific vulnerabilities of cancer cells. While cytotoxic chemotherapy — agents that kill rapidly dividing cells through direct DNA damage, antimetabolite mechanisms, or mitotic inhibition — remains central to many cancer treatment regimens, it is increasingly used in combination with or as bridging therapy before targeted agents and immunotherapies, and the clinical pharmacist’s role in oncology pharmacy requires deep knowledge of all these drug classes.

Cytotoxic agents include alkylating agents (cyclophosphamide, ifosfamide, busulfan, carboplatin, cisplatin, oxaliplatin), which form covalent cross-links with DNA, distorting the double helix and preventing replication and transcription; antimetabolites (methotrexate, 5-fluorouracil, gemcitabine, cytarabine, pemetrexed), which structurally mimic nucleotides or folate cofactors and inhibit enzymes essential for DNA synthesis; topoisomerase inhibitors (irinotecan, topotecan, etoposide, doxorubicin), which trap the topoisomerase enzyme-DNA complex and prevent re-ligation of DNA strand breaks; and taxanes and vinca alkaloids (paclitaxel, docetaxel, vinorelbine, vincristine), which bind tubulin and disrupt microtubule dynamics, preventing chromosome segregation during mitosis. These agents are selectively toxic to rapidly dividing cells — which include cancer cells, but also bone marrow progenitors, gastrointestinal mucosal cells, and hair follicle cells — producing the characteristic side effects of chemotherapy: myelosuppression (with risk of infection, bleeding, and anemia), mucositis, nausea and vomiting, and alopecia.

Immune checkpoint inhibitors — particularly PD-1 inhibitors (pembrolizumab, nivolumab), PD-L1 inhibitors (atezolizumab, durvalumab, avelumab), and CTLA-4 inhibitors (ipilimumab, tremelimumab) — have produced durable remissions in a proportion of patients with melanoma, non-small cell lung cancer, urothelial carcinoma, renal cell carcinoma, microsatellite-instability high (MSI-H) tumours, and many other cancer types. These drugs work by removing the brakes that cancers use to evade immune destruction — the PD-1/PD-L1 axis, when activated by tumour-expressed PD-L1 binding to T-cell PD-1, suppresses T-cell anti-tumour activity; blocking PD-1 or PD-L1 restores T-cell killing. The unique adverse effect profile of checkpoint inhibitors — immune-related adverse events (irAEs) including colitis, hepatitis, pneumonitis, endocrinopathies (hypothyroidism, adrenal insufficiency, type 1 diabetes), dermatitis, and, rarely, carditis and neurological syndromes — reflects the unrestrained immune activation these drugs produce and requires pharmacist expertise in recognition, grading (CTCAE grading), and management (corticosteroids for high-grade irAEs, with immunosuppressive rescue agents such as infliximab for steroid-refractory colitis).